Project Details
Description
NRG-GY023: A RANDOMIZED PHASE II TRIAL OF TRIPLET THERAPY (A PD-L1 INHIBITOR DURVALUMAB (MEDI4736) IN COMBINATION WITH OLAPARIB AND CEDIRANIB) COMPARED TO OLAPARIB AND CEDIRANIB OR DURVALUMAB (MEDI4736) AND CEDIRANIB OR STANDARD OF CARE CHEMOTHERAPY IN W
| Status | Active |
|---|---|
| Effective start/end date | 10/29/21 → 2/28/25 |
Funding
- NRG ONCOLOGY FOUNDATION, INC.
- NIH NATIONAL CANCER INSTITUTE (NCI)
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.